News

The sBLA is based on results from the Phase III RADIANCE study that demonstrated treatment with Lucentis provided superior visual acuity gains in people with mCNV compared to

Under the collaboration deal, Transgene will sponsor a phase 1/2 study to assess its therapeutic vaccine candidate TG4001 together with Merck and Pfizer's immunotherapy avelumab to treat human

Under the collaboration, Takeda will provide EnGeneIC with an upfront access fee and research funding to explore the feasibility of the EDV technology for the development of immunomodulatory

Aprea Therapeutics AB president and CEO Christian Schade said: "The initiation of the Phase II clinical study marks an important milestone for Aprea. "We are committed to developing and

SCIB2 will be studied in combination with a checkpoint inhibitor and follow the publication of data in journal OncoImmunology, which showed the drug demonstrated potent anti-tumour immunity. Data

The sBLA was submitted by Genmab's licensing partner, Janssen Biotech, Inc. in August 2016. Priority Review is an FDA designation for drugs that treat a serious condition and

The findings will be presented during a poster discussion session (Abstract #774PD) on October 9 at the European Society for Medical Oncology (ESMO) 2016 Congress, which is being

The injection has been approved as a short-term replacement therapy for oral carbamazepine formulations in adults with certain seizure types when oral administration is temporarily not possible. It

The agreement was reached through the Special Protocol Assessment (SPA) process. A SPA is an acknowledgement by FDA that the design and planned analysis of the Company's pivotal